Goldman Sachs Maintains Buy on 2seventy bio, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $27 to $24.
August 15, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on 2seventy bio but lowers the price target from $27 to $24.
The news is directly about 2seventy bio and its price target being lowered by Goldman Sachs. While the Buy rating is maintained, the lower price target could indicate a slower growth expectation, which might impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100